-
EP4103692
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4103692
| EP4103692 - NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES; AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 18.11.2022 Database last updated on 24.08.2024 | |
| Former | The international publication has been made Status updated on 20.08.2021 | Most recent event Tooltip | 01.05.2024 | Supplementary search report | published on 29.05.2024 [2024/22] | Applicant(s) | For all designated states Bowroju, Suresh, Kuarm 325 Jack Stephens Dr. Uams Biomed-i Little Rock, AR 72205 / US | For all designated states Crooks, Peter 22 Ridgefield Cove Little Rock, AZ 72223 / US | For all designated states Penthalla, Narsimha 1300 Westhampton Drive Little Rock, AZ 72211 / US | For all designated states Ayyadevara, Srinivas 14203 Overcreek Pass Little Rock, AZ 72211 / US | For all designated states Guzman, Monica 450E 63rd St. Apartment 11a New York, NY 10065 / US | For all designated states Shmookler Reis, Robert, J. 14 Pinnacle View Cove Little Rock, AZ 72223 / US | For all designated states Lopes, Eloisi 413 East 69th Street New York, NY 10021 / US | For all designated states Kakraba, Samuel 629 Jack Stephens Drive Little Rock, AZ 72205 / US | [2022/51] | Inventor(s) | 01 /
see applicant ... | [2022/51] | Representative(s) | CH Kilger Anwaltspartnerschaft mbB Fasanenstraße 29 10719 Berlin / DE | [2022/51] | Application number, filing date | 21754449.3 | 12.02.2021 | [2022/51] | WO2021US17970 | Priority number, date | US202062976604P | 14.02.2020 Original published format: US 202062976604 P | [2022/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021163572 | Date: | 19.08.2021 | Language: | EN | [2021/33] | Type: | A1 Application with search report | No.: | EP4103692 | Date: | 21.12.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.08.2021 takes the place of the publication of the European patent application. | [2022/51] | Search report(s) | International search report - published on: | US | 19.08.2021 | (Supplementary) European search report - dispatched on: | EP | 30.04.2024 | Classification | IPC: | C12N5/071, C12N5/077, C12N5/0775 | [2022/51] | CPC: |
C07D417/12 (EP,US);
C07D285/08 (EP,US);
A61P25/28 (US);
A61P29/00 (EP);
A61P35/00 (EP);
A61P35/02 (US);
C07D493/04 (EP,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/51] | Title | German: | NEUARTIGE TDZD-ANALOGE ALS MITTEL ZUR VERZÖGERUNG, VORBEUGUNG ODER UMKEHRUNG VON ALTERSBEDINGTEN KRANKHEITEN SOWIE ALS MITTEL GEGEN KREBS UND LEUKÄMIE | [2022/51] | English: | NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES; AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS | [2022/51] | French: | NOUVEAUX ANALOGUES DE TDZD EN TANT QU'AGENTS QUI RETARDENT, PRÉVIENNENT OU INVERSENT DES MALADIES ASSOCIÉES À L'ÂGE; ET EN TANT QU'AGENTS ANTICANCÉREUX ET ANTILEUCÉMIQUES | [2022/51] | Entry into regional phase | 14.09.2022 | National basic fee paid | 14.09.2022 | Search fee paid | 14.09.2022 | Designation fee(s) paid | 14.09.2022 | Examination fee paid | Examination procedure | 14.09.2022 | Examination requested [2022/51] | 06.04.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 09.02.2023 | Renewal fee patent year 03 | 13.02.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2005024755 (DECIPHERA PHARMACEUTICALS LLC [US], et al) [A] 1,4-6,13,18,20,39-76* , especially: pg 51, In 25-35, Example 78. *; | [A] - Jessica Nicole Ponder, "Phenotypic Screening of Parthenolide Derivatives Reveals the Chemoprotective Role of Galectin-1 in Acute Myeloid Leukemia", Thesis, (20180101), ISBN 978-0-438-00313-2, pages 1 - 240, XP055847532 [A] 1,4-6,13,18,20,39-76 * , BSK 1-40. * | [A] - Anna Martinez , Mercedes Alonso , Ana Castro , Concepcion Perez , Francisco J Moreno, "First Non-ATP Competitive Glycogen Synthase Kinase 3-beta (GSK-3-beta) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease", Journal of Medicinal Chemistry, US, (20020101), vol. 45, no. 6, doi:10.1021/jm011020u, ISSN 0022-2623, pages 1292 - 1299, XP002292084 [A] 1,4-6,13,18,20,39-76 * , especially: pg 1294, Table 1, compound 14. * DOI: http://dx.doi.org/10.1021/jm011020u |